Abstract
Neuromyelitis optica (NMO) is an idiopathic inflammatory demyelinating disease, characterized by optic neuritis and myelitis. NMO is a very uncommon and serious neurologic manifestation of Sjögren's syndrome. We report on a 32-year-old female with NMO as central nerve system involvement of Sjögren's syndrome. She had a transverse myelitis ten years ago and did not have symptoms for a long period of time. She visited the emergency center because of worsening weakness of both limbs. She had an appendectomy three days ago before hospitalization. Cervical spinal magnetic resonance imaging showed increased signal intensity in T2-weighted images from the cervical (C2) to the upper thoracic (T4) spinal cord. As serum NMO-IgG was positive, we diagnosed neuromyelitis optica and treated with high dose steroid, but failed. Therefore, we treated with plasmapheresis and the patient was discharged without any neurological deficits.
References
1. Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjögren's syndrome. Medicine (Baltimore). 1982; 61:247–57.
3. Minagar A, Alexander JS, Fowler MR, Long AC, Kelley RE. Devic disease: clinical course, pathophysiology, and management. Pathophysiology. 2002; 9:33.
4. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 125:1450–61.
5. Williams CS, Butler E, Román GC. Treatment of myel-opathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol. 2001; 58:815–9.
6. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6:805–15.
7. Protti A, Erminio C, Piccolo I, Spreafico C, Colombo F, Ghezzi A. An unusual case with relapsing neuromyelitis optica associated with undifferentiated connective tissue disease. Neurol Sci. 2004; 25(Suppl 4):S383–5.
8. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364:2106–12.
9. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66:1485–9.
10. Koo YS, Yoo JK, Kwon DY, Park MH, Koh SB, Kim BJ, et al. Neuromyelitis optica with positive anti-Ro and anti-La antibodies. J Korean Neurol Assoc. 2009; 27:446–8.
11. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58:143–6.
12. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998; 51:1219–20.
13. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65:1443–8.